Drugs / 89Zr-MMOT0530A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01832116 | Mar 2013 → May 2014 | ovarian neoplasm, pancreatic neoplasm | University Medical Center Groningen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-MMOT0530A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01832116 ↗ |
| Modality | Monoclonal antibody | “MMOT0530A is a monoclonal antibody” NCT01832116 ↗ |
| Route | Other | “Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points” NCT01832116 ↗ |